A retrospective analysis of the indication of extended-field irradiation for cervical cancer patients who had previously undergone concurrent chemoradiotherapy

A retrospective analysis of the indication of extended-field irradiation for cervical cancer patients who had previously undergone concurrent chemoradiotherapy - Analysis on adaptation of prophylactic expansion irradiation in cervical cancer with CCRT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032949

Enrollment

600

Registered

2018-06-15

Start date

2018-05-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical carcinoma

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with cervical cancer from January 2009 to December 2014 who had undergone CCRT using platinum single agent. (2) Metastatic cervical cancer was excluded. (3).FIGO stage IB1 to IVA were included.. (4) All cases of squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma were included. (5) Pelvic MRI (T1, T2, DWI) was performed before CCRT, as well as enhanced CT (if possible PET) for comprehensive review from the chest to lower abdomen (PET-CT, PET-MR if possible) (6) Minimum requirements for imaging studies were, CT: number of detectors (more than 64 rows), enhanced CT (with or without dynamic contrast-enhanced imaging), MRI: magnetic field of1.5 T or more, diffusion weighted image required.

Exclusion criteria

Exclusion criteria: Metastatic cervical cancer

Design outcomes

Primary

Measure	Time frame
1. Pathological tissue subtype, age, FIGO advanced stage, TNM classification 2. Initial treatment (CCRT) start date, treatment end date, treatment details (dose, irradiation method, chemotherapy drug (limited to platinum single agent) and dose), paraaortic lymph node (PAN) biopsy 3. Status of residual disease / recurrence, date of diagnosis of recurrence / relapse, site of recurrence (pelvic, distant, pelvic LN, paraaortic LN) 4. Last confirmed date of survival, day of death b. Radiation therapy: CCRT (irradiation field, irradiation method, Linac, electron beam, total dose) c. Chemotherapy: type of regimen, number of cycles d. Imaging evaluation 1. Size of tumor (diameter, volume) (assessed using MRI) 2. ADC value of tumor 3. Tumor growth type (intramural, extramural) (MRI) 4. Presence or absence of uterine corpus invasion (MRI) 5. Degree of interstitial infiltration (1/2 or more or less) (MRI) 6. Presence or absence of cervical parametrial invasion (MRI) 7. Presence or absence of lymph node metastasis, position and number of enlarged lymph nodes according to CT, MR, or PET scans 8. SUV max of tumor according to PET 9. Presence and presence of other metastases	—

Measure

Time frame

1. Pathological tissue subtype, age, FIGO advanced stage, TNM classification 2. Initial treatment (CCRT) start date, treatment end date, treatment details (dose, irradiation method, chemotherapy drug (limited to platinum single agent) and dose), paraaortic lymph node (PAN) biopsy 3. Status of residual disease / recurrence, date of diagnosis of recurrence / relapse, site of recurrence (pelvic, distant, pelvic LN, paraaortic LN) 4. Last confirmed date of survival, day of death b. Radiation therapy: CCRT (irradiation field, irradiation method, Linac, electron beam, total dose) c. Chemotherapy: type of regimen, number of cycles d. Imaging evaluation 1. Size of tumor (diameter, volume) (assessed using MRI) 2. ADC value of tumor 3. Tumor growth type (intramural, extramural) (MRI) 4. Presence or absence of uterine corpus invasion (MRI) 5. Degree of interstitial infiltration (1/2 or more or less) (MRI) 6. Presence or absence of cervical parametrial invasion (MRI) 7. Presence or absence of lymph node metastasis, position and number of enlarged lymph nodes according to CT, MR, or PET scans 8. SUV max of tumor according to PET 9. Presence and presence of other metastases

—

Countries

Japan

Contacts

Public ContactAkiko Tozawa

St. Marianna University School of Medicine Obstetrics and Gynecology

a2ono@marianna-u.ac.jp0449778111

Outcome results